Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIB Breast CancerInterventions:   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Radiation: Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life AssessmentSponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   American College of Surgeons;   North Central Cancer Treatment Group;   Cancer and Leukemia Group B;   NSABP Foundation Inc;   NCIC Clinical Trials GroupActive, not recruiting - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conclusions: Use of the 21-gene rs assay could be a cost-effective strategy for Ontario patients with estrogen receptor-positive, her2-negative early bca and 1-3 positive lns. PMID: 31708649 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Cancers, Vol. 11, Pages 1669: Breast Cancer during Pregnancy—Current Paradigms, Paths to Explore Cancers doi: 10.3390/cancers11111669 Authors: Ayelet Alfasi Irit Ben-Aharon Breast cancer is the most common form of malignancy in pregnant women. The prevalence of pregnancy-associated breast cancer (PABC) is up to 0.04% of pregnancies and is expected to rise in developed countries. PABC represents a unique clinical scenario which requires a delicate balance of risks and benefits for both maternal and fetal well-being. Currently, there is paucity of data regarding the short- and long-term outcomes of in-utero e...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Development of recurrence risk score using 95‑gene classifier and its application to formalin‑fixed paraffin‑embedded tissues in ER‑positive, HER2‑negative and node‑negative breast cancer. Oncol Rep. 2019 Oct 07;: Authors: Naoi Y, Saito Y, Kishi K, Shimoda M, Kagara N, Miyake T, Tanei T, Shimazu K, Kim SJ, Noguchi S Abstract We previously developed a 95‑gene classifier (95GC) to classify ER‑positive/HER2‑negative/node‑negative (ER+/HER2‑/N0) breast cancer as high‑ and low‑risk. The present study aimed to devise a 95GC recurrence score (95GCRS) to estimate recurrence risk ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
ConclusionsThe present study demonstrates that, in plasma-derived exosomes, high  baseline CDK4 mRNA levels are associated with response to palbociclib plus hormonal therapy, while the increase in TK1 and CDK9 mRNA copies/ml is associated with clinical resistance.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractBackgroundA high percentage of breast cancer patients in the Asia-Pacific ( ∼42%) and Middle East (∼50%) regions are aged 50 years or younger. Although a high proportion of younger patients with endocrine-responsive metastatic disease are treated initially with cytotoxic chemotherapy (CT) in routine general practice, data from phase III trials have shown higher response rates and longer progression-free survival with endocrine therapy (ET) in combination with CDK4/6 inhibitor versus single agent ET. Due to lack of direct evidence, trials in pre-/perimenopausal advanced breast cancer are thus necessary to as...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundAim: To clarify the clinicopathological characters and treatments and prognosis in elderly breast cancer patients using the Japanese Breast Cancer Registry (JBCR) system.MethodsWe reviewed data from JBCR, which is the nation-wide registry of newly diagnosed and operated primary breast cancer patients in Japan. To clarify its characteristics, we compared elderly patients aged 75 and over (elderly) with aged from 65 to 74 (young-old; y-o) and that from 55 to 64 (post-menopausal; p-m), respectively.ResultsIn total 132,240 cases diagnosed between 2004 and 2011 were reviewed (elderly; n  = 27,385...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundCLEOPATRA study demonstrated the efficacy and safety of pertuzumab (P) + trastuzumab (T) + docetaxel (D) but efficacy results of Japanese subgroup weren ’t consistent with the whole study results. A phase IV, multicenter, prospective, COMACHI study was conducted in Japan to re-confirm the efficacy and safety of P+T+D demonstrated in the CLEOPATRA study.MethodsPatients (pts) with HER2-positive breast cancer who were diagnosed as Stage IV or recurred more than a year after (neo)adjuvant taxane chemotherapy completion were enrolled. Pts were administered study drugs intravenously every 3 weeks. Discont...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Drug Res (Stuttg) DOI: 10.1055/a-0892-4118HER2-positive breast tumors are found in 25–30% of patients with breast cancer and are characterized by aggressive course and reduced sensitivity to both chemotherapy and hormone therapy. The aim of the work was to study the possibilities of enhancing the therapeutic effect of anti-estrogen drug toremifene by combining it with biguanide, metformin, on the HER2-positive breast cancer model in FVB/N HER-2/neu transgenic mouse. Male FBV/N mice with intramuscularly transplanted HER2-positive mammary gland tumor from a female mouse of the same strain have been given toremifene (30...
Source: Drug Research - Category: Drugs & Pharmacology Authors: Tags: Original Article Source Type: research
Authors: Mangone L, Mancuso P, Tagliabue G, Filiberti RA, Carrozzi G, Iacovacci S, Mazzucco W, Tumino R, Minicozzi P, Sant M, Giorgi Rossi P Abstract OBJECTIVE: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I-III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. METHODS: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009-2013). Included were 3546 women aged
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
yong-Huey Lai Endometrial cancer incidence rates are growing, especially in countries with rapid socioeconomic transitions. Despite recent advances in chemotherapy, hormone therapy, and targeted therapy, advanced/recurrent disease remains a clinical challenge. Palbociclib—a selective inhibitor of cyclin-dependent kinases (CDK) 4/6—has therapeutic potential against estrogen receptor (ER)-positive and HER2-negative breast cancer. However, the question as to whether it can be clinically useful in endometrial cancer remains open. Here, we show that combined treatment with palbociclib and megesterol acet...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Hormonal Therapy | Hormones | Research | Women